← Back to Search

Topical Agent

ATI-1777 for Atopic Dermatitis

Phase 2
Waitlist Available
Research Sponsored by Aclaris Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to day 42
Awards & highlights

Study Summary

This trial is testing a new medication for people with moderate or severe eczema. The drug will be applied either once or twice a day for 4 weeks.

Eligible Conditions
  • Atopic Dermatitis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to day 42
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to day 42 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage change from baseline in Eczema Area and Severity Index Score (EASI) score at Week 4 (Day 28)
Secondary outcome measures
Change from baseline in Body Surface Area (BSA) at each post-baseline study visit
Change from baseline in Itch Numerical Rating Scale (PP NRS) from baseline to Day 28
Change from baseline in vIGA score at each post-baseline study visit
+4 more

Trial Design

6Treatment groups
Experimental Treatment
Placebo Group
Group I: ATI-1777 topical solution 2.0% w/w (QD)Experimental Treatment1 Intervention
ATI-1777 topical solution 2.0% w/w, once daily
Group II: ATI-1777 topical solution 2.0% w/w (BID)Experimental Treatment1 Intervention
ATI-1777 topical solution 2.0% w/w, twice daily
Group III: ATI-1777 topical solution 1.0% w/w (BID)Experimental Treatment1 Intervention
ATI-1777 topical solution 1.0% w/w, twice daily
Group IV: ATI-1777 topical solution 0.5% w/w (BID)Experimental Treatment1 Intervention
ATI-1777 topical solution 0.5% w/w, twice daily
Group V: Vehicle (BID)Placebo Group1 Intervention
Vehicle topical solution, twice daily
Group VI: Vehicle (QD)Placebo Group1 Intervention
Vehicle topical solution, once daily
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ATI-1777 2.0% w/w
2022
Completed Phase 2
~250
ATI-1777 1.0% w/w
2022
Completed Phase 2
~250
ATI-1777 0.5% w/w
2022
Completed Phase 2
~250

Find a Location

Who is running the clinical trial?

Aclaris Therapeutics, Inc.Lead Sponsor
31 Previous Clinical Trials
4,474 Total Patients Enrolled

Media Library

ATI-1777 (Topical Agent) Clinical Trial Eligibility Overview. Trial Name: NCT05432596 — Phase 2
Atopic Dermatitis Research Study Groups: ATI-1777 topical solution 2.0% w/w (BID), ATI-1777 topical solution 1.0% w/w (BID), ATI-1777 topical solution 0.5% w/w (BID), Vehicle (BID), ATI-1777 topical solution 2.0% w/w (QD), Vehicle (QD)
Atopic Dermatitis Clinical Trial 2023: ATI-1777 Highlights & Side Effects. Trial Name: NCT05432596 — Phase 2
ATI-1777 (Topical Agent) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05432596 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research accessible to individuals who have surpassed the age of forty?

"Based on the criteria, participants must be between 12 and 65 years of age to join this medical trial."

Answered by AI

Is there an established presence of this trial across North America?

"In its current iteration, this medical trial is enrolling patients from 34 sites dispersed throughout the United States. Dallas, Normal and Encinitas are some of the cities that have a site participating in the study. It is recommended to pick a location closest to you so as to reduce travel demands if chosen for participation."

Answered by AI

Do any potential risks accompany the administration of ATI-1777 0.5% w/w?

"Our team has rated the safety of ATI-1777 0.5% w/w as a 2, due to its Phase 2 status and limited evidence for efficacy."

Answered by AI

Might I be a viable candidate for this experiment?

"This dermatitis study is recruiting up to 240 participants, aged 12-65. In order for a patient to be eligible, they must understand the Institutional Review Board approved informed consent/assent form and agree to its terms; additionally, male patients or female non-pregnant and non-nursing individuals between 12 - 65 years of age will be considered. Those enrolled should have had at least 6 months of AD prior to the Screening Visitation with no significant flares during the previous 4 weeks."

Answered by AI

How many participants have been inducted into this research initiative?

"Affirmative. According to the information hosted on clinicaltrials.gov, this research endeavour is actively recruiting participants as of August 31st 2022; it was first posted on May 11th 2022 with a goal to enrol 240 patients from 34 different sites."

Answered by AI

Is it currently possible to enroll in this investigation?

"Yes, the information available on clinicaltrials.gov confirms that enrolment for this medical study is currently underway. This project was initially posted in May of 2022 and has been revised as recently as August 31st of 2022. It aims to find 240 volunteers recruited from 34 different sites."

Answered by AI

Who else is applying?

What state do they live in?
California
How old are they?
18 - 65
What site did they apply to?
Aclaris Investigational Site
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis
2022. "Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05432596.
~86 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top